SCHEMBL5183997

SCHEMBL5183997

COC(=O)c1cc(Br)cn(Cc2ccc(Cl)cc2)c1=O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 4/20 0.52
ALDH1A1 P00352 2/20 0.52
USP2 O75604 1/20 0.49
CNR1 P21554 1/20 0.48
CNR2 P34972 1/20 0.48
KDM4E B2RXH2 2/20 0.47
HPGD P15428 1/20 0.46
MAPT P10636 4/20 0.44
POLB P06746 2/20 0.44
HIF1A Q16665 1/20 0.44
GAA P10253 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
HSP90AA1 P07900 1/20 0.43
HSP90B1 P14625 1/20 0.43
PDPK1 O15530 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18584511 0.88 ADRA1D (0.54) MAPK10ALDH1A1USP2CNR1CNR2
SCHEMBL31418373 0.88 ADRA1D (0.52) MAPK10ALDH1A1USP2KDM4EHPGD
SCHEMBL988302 0.83 MAPT (0.49) MAPK10ALDH1A1USP2MAPTGAA
SCHEMBL5450881 0.81 CNR1 (0.51) MAPK10ALDH1A1CNR1CNR2KDM4E
SCHEMBL5435818 0.80 CNR1 (0.57) MAPK10ALDH1A1CNR1CNR2KDM4E
SCHEMBL19768920 0.79 BRD4 (0.55) MAPK10ALDH1A1USP2CNR1CNR2
SCHEMBL15241737 0.79 BRD4 (0.54) MAPK10ALDH1A1KDM4EHPGDMAPT
SCHEMBL4387866 0.77 KDM4E (0.53) ALDH1A1KDM4EHPGDMAPTPOLB
SCHEMBL986728 0.77 MAPT (0.43) MAPK10ALDH1A1KDM4EHPGDMAPT
SCHEMBL18617796 0.77 BRD4 (0.66) CNR1CNR2HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799646-B1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS JANSSEN PHARMACEUTICALS INC (US) 2014-12-10 EP disclosed
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 US disclosed
US-8399493-B2 Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors Janssen Pharmaceuticals, Inc. (US) 2013-03-19 US disclosed
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS Janssen Pharmaceuticals, Inc. 2007-09-13 US disclosed
EP-1799646-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-27 EP disclosed
WO-2006030032-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRM3 MAPK10 2467/4885ALDH1A1 3403/4885USP2 3185/4885
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRIA2 MAPK10 1704/4885ALDH1A1 2717/4885USP2 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.